Author pages are created from data sourced from our academic publisher partnerships and public sources.
Review of 1027 patients with newly diagnosed multiple myeloma.
OBJECTIVE To determine the clinical and laboratory features of newly diagnosed multiple myeloma. PATIENTS AND METHODS Records of all patients in whom multiple myeloma was initially diagnosed at the… Expand
POEMS syndrome: definitions and long-term outcome.
The POEMS syndrome (coined to refer to polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) remains poorly understood. Ambiguity exists over the features necessary to establish… Expand
Improved survival in multiple myeloma and the impact of novel therapies.
Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for… Expand
Primary systemic amyloidosis: clinical and laboratory features in 474 cases.
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for immunoglobulin light‐chain amyloidosis… Expand
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038… Expand
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
- A. Dispenzieri, M. Gertz, +11 authors A. Jaffe
- Journal of clinical oncology : official journal…
- 15 September 2004
PURPOSE Primary systemic amyloidosis (AL) is a multisystemic disorder resulting from an underlying plasma cell dyscrasia. There is no formal staging system for AL, making comparisons between studies… Expand
Genetic aberrations and survival in plasma cell leukemia
Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma… Expand
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.
Aneuploid is ubiquitous in multiple myeloma (MM), and 4 cytogenetic subcategories are recognized: hypodiploid (associated with a shorter survival), pseudodiploid, hyperdiploid, and near-tetraploid… Expand
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is part of a spectrum of monoclonal plasma… Expand